PharmaMar (Spain)

Recent papers from PharmaMar (Spain)

1. Inflammatory Pseudotumour in Common Seal ( Phoca vitulina ): A Case ReportVeterinary Medicine and Science · 2026
2. Lurbinectedin plus irinotecan in pretreated gastroenteropancreatic neuroendocrine neoplasms: results of a phase II expansion cohortESMO Open · 2026
3. Genome-wide evidence for the local ancestry of the Agotes from Navarra, SpainiScience · 2026
4. Antitumor activity of novel transcriptional inhibitors ecubectedin and PM54 in soft tissue sarcoma patient-derived xenograftsCancer Research Communications · 2026
5. Investigating the role of G-quadruplex-associated duplex stem loops in Trabectedin’s mechanism of actionScientific Reports · 2026
6. The structures of ecteinascidin anticancer agents bound to DNA shed light on their mechanism of actionNucleic Acids Research · 2026
7. The ITCC-P4 PDX Platform Enables Preclinical Testing of Pediatric CancersCancer Research · 2026
8. Bleeding and Ischemic Risks of Ticagrelor Monotherapy After Coronary InterventionsJournal of the American College of Cardiology · 2023
9. Convergent Total Synthesis of PM742 and SAR-Guided Development of the Clinical Candidate PM534Marine Drugs · 2026
10. Pooled safety analysis of lurbinectedin plus irinotecan in patients with advanced solid tumorsInvestigational New Drugs · 2026
11. Abstract 2981: PM54 targets oncogenic transcriptional networks across multiple cancer typesCancer Research · 2026
12. Abstract 2841: PM54 reshapes the tumor microenvironment to potentiate checkpoint blockadeCancer Research · 2026
13. Abstract 5754: PM54 suppresses WNT/β-catenin signaling and synergizes with chemotherapy in gastric cancer modelsCancer Research · 2026
14. Isolation and First Total Synthesis of PM100618 and PM110049, Two Structurally Distinct Marine-Derived Anticancer Oxazole DerivativesThe Journal of Organic Chemistry · 2026
15. Combination of Lurbinectedin Plus Irinotecan: Preclinical and Early Clinical Results in Patients With Relapsed SCLCJournal of Thoracic Oncology · 2026
16. Gemcitabine plus selinexor in selective advanced sarcomas: a phase I of the Spanish group for research on sarcoma studyNature Communications · 2026
17. Plitidepsin in combination with dexamethasone (ADMYRE trial) versus an external control arm of pomalidomide plus dexamethasone in patients with relapsed/refractory multiple myelomaAnnals of Hematology · 2026
18. Clarifying INSTINCT: Switching From Dolutegravir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Shows Comparable Inflammatory and Weight OutcomesClinical Infectious Diseases · 2025
19. Drug screening reveals differential drug response in primary and metastatic clear cell sarcomaCancer Letters · 2025
20. Randomized Phase III Study (ADMYRE) of Plitidepsin in Combination with Dexamethasone vs. Dexamethasone Alone in Relapsed/Refractory Multiple Myeloma: Results for Patients Aged <75 YearsCancers · 2025